Business Wire

MA-SKYHOOK

4.3.2021 15:02:09 CET | Business Wire | Press release

Share
Leading Supply Chain Visibility Company Tive Selects Skyhook for Location Positioning

Skyhook, the leading independent Wi-Fi, Cell and Hybrid location provider, has been chosen by Tive® to enhance the hyper-accurate location of in-transit shipments. Tive helps logistics professionals actively monitor the location and condition of loads with data on location, temperature, shock, light exposure, and humidity. Skyhook's Precision Location solution will replace and supplement existing location sources on specific models of Tive shipment trackers . With Skyhook's location positioning, Tive's customers gain greater visibility into how materials and equipment move throughout their supply chains.

Location tracking helps shippers and logistics service providers (LSP) understand the overall supply chain flow, identify and anticipate disruptions, predict delivery ETAs, and allow for constant improvements through comprehensive analytics and optimization. Tive provides real-time in-transit visibility for eliminating preventable delays and damage and chose Skyhook based on their hybrid location approach, ability to provide location positioning in various environments, and low impact on tracker battery life. Skyhook will be used across the Tive Data Cloud and Open Visibility Network (OVN), assuring that loads are visible even when entering locations where traditional GPS would fail, such as when shipments enter a warehouse.

Skyhook's Precision Location solution, which triangulates cellular, and Wi-Fi signals along with GPS to calculate a tracker's location, extends real-time visibility into a shipment's current location. The integration of Skyhook services delivers real benefits such as improved inventory control, loss and theft prevention by accessing immediate location information, greater operational efficiency, and overall improved visibility.

"Skyhook is thrilled to work with Tive to make it easier for businesses to track and monitor their modern supply chain," said Craig Waggy, CEO, Skyhook. "Our unique hybrid approach is a great fit for asset tracking companies looking to understand how their products are moving across the globe."

"The next generation of in-transit visibility is adding more ways to stream meaningful data in real-time, so logistics professionals can actively manage shipments and avoid delays and damage,” said Lennon Acosta, Sr. Director, software engineering, Tive. "Hyper-accurate location and connectivity is a cornerstone - and Skyhook delivers both. And our Open Visibility Network delivers that data to mutual customers of project44 and FourKites , creating a new industry standard in in-transit visibility.”

Skyhook and Tive look forward to continuing their partnership with future products. To find out more about Skyhook's location solution for asset tracking, visit this page: https://www.skyhook.com/asset-tracking

About Skyhook:

Skyhook is the worldwide independent leader in location technology, operating the world's largest independent location network, consisting of 5.1 billion geolocated Wi-Fi hotspots and 200 million cell towers. Skyhook processes tens of billions of location transactions, serving devices, apps, wearables, brands and advertising platforms with precise and accurate location data and intelligence. Skyhook, through its parent company Skyhook Holding, Inc., operates as a wholly owned subsidiary of Liberty Broadband Corporation. To learn more visit www.skyhook.com .

About Tive

Tive is a leading provider of real-time supply chain visibility insights that help logistics professionals actively manage their in-transit shipments’ location and condition. With Tive, shippers and logistics service providers (LSP) eliminate preventable delays, damage, and shipment failures. Tive’s solution provides data generated by its industry-leading trackers allowing clients to actively optimize their shipments, improve their customers’ experience, and unlock supply chain insights in an actionable real-time manner. For more information, visit www.tive.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye